Studies demonstrate how Volition's Nu.Q®H3K27Me3 biomarker, when combined with ctDNA, may improve the prognostic value for overall survival and could help inform treatment decisions in NSCLC; and how ...
ELCC is a program of the European Society for Medical Oncology (ESMO ... M.D., CEO of MAIA. "Our poster features our latest findings on cytokine Interleukin-6 (IL-6) as a potential predictive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback